The Applications of Monoclonal Antibodies in Neuro-Oncology
- 37 Downloads
Central nervous system (CNS) malignancies represent one ofthe most devastating forms of cancer. Malignant gliomas, the most commonly occurring primary tumor of the CNS, have a particularly bleak prognosis despite surgery and combined radiation and chemotherapy (1, 2). Immunological approaches to diagnosis and treatment have seemed attractive, but in the past have been frustrated by technological limitations (3, 4). Monoclonal antibody methodology offers major advantages over conventional methods of antiserum production: a practically unlimited source of homogeneous, highly specific reagent which may be prepared using impure or complex antigens. This has led to a new age in neuroimmunology and neuro-oncology, with the potential for better understanding of the basic cell biology of CNS neoplasia, and for improvement in diagnosis, imaging, and therapy.
Key wordsMonoclonal antibody glioma glioma-associated antigen xenograft
Unable to display preview. Download preview PDF.
- 2.Walker (M.D.), Alexander (E.), Hunt (W.E.), MacCarty (C.S.), Mahaley (M.S.), Norrel (H.A.), Owens (G.), Ransahoff (J.), Wilson (C.B.), Gehan (E.A.), Strike (T.A.): Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J. Neurosurg., 43: 333–343 (1978).Google Scholar
- 3.Mahaley (M.S.), Mahaley (J.L.), Day (E.D.): Localization of radioantibodies in human brain tumors II. Radioautography. Cancer Res., 2: 779–793 (1965).Google Scholar
- 6.Mclendon (R.E.), Burger (P.C.), Pegram (C.N.), Eng (L.F.), Bigner (D.D.): The immunohistochemical application of three anti-GFAP monoclonal antibodies to formalin-fixed paraffin-embedded normal and neoplastic brain tissues. J. Neuropathol. Exp. Neurol., 45: 692–703 (1986).PubMedCrossRefGoogle Scholar
- 7.Vick (W.W.), Bigner (S.H.), Wikstrand (C.J.), Bullard (D.E.), Kemshead (J.), Coakham (H.G.), Schlom (J.), Johnston (W.W.), Bigner (D.D.): The use of a panel of monoclonal antibodies in the evaluation of cytologic specimens from the central nervous system. In press, Acta Cytol (1986).Google Scholar
- 10.Wikstrand (C.J.), Mclendon (R.E.), Carrel (S.), Kemshead (J.T.), Mach (J.P.), Coakham (H.B.), Tribolet (N. de), Bullard (D.E.), Zalutsky (M.R.), Bigner (D.D.): Comparative localization of glioma reactive-monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model. In press, J. Neuroimmunol. (1986).Google Scholar
- 13.Allan (P.M.), Garson (J.A.), Harper (E.L.), Asser (U.), Cookham (H.B.), Brownell (B.), Kemshead (J.T.): Biological characterization and clinical application of a monoclonal antibody recognizing an antigen restricted to neuro-ectodermal tissues. Int. J. Cancer 31: 591–598 (1983).PubMedCrossRefGoogle Scholar
- 16.Davies (A.G.), Richardson (R.B.), Bourne (S.P.), Kemshead (J.T.), Coakham (H.B.): Immunolocalisation of human brain tumours. in Bleehan n (E.D.) Tumours of the Brain (Springer-Verlag, 1986).Google Scholar